Strategic Merger Medimaps Group recently entered a strategic merger with Radiobotics ApS, signaling potential expansion of complimentary AI-driven MSK radiology capabilities and cross-selling opportunities to radiology systems and clinics already using Radiobotics solutions.

Global Adoption TBS Osteo is already adopted in 90 countries with over 4.5 million procedures annually, indicating a validated product-market fit and a ready-made case for expanding adoption in hospitals and clinics seeking bone health assessment tools.

Reimbursement Milestone US Medicare Category 1 reimbursement for TBS Osteo enhances payer credibility and may reduce procurement barriers, presenting a strong talking point for targeted outreach to U.S. health systems, academic centers, and radiology networks.

New Product Opportunities Recent launches including TBS Reveal and AI-based image processing updates create upsell and cross-sell avenues to existing customers, as well as a pathway to target radiology and osteoporosis imaging departments seeking advanced analytics.

Growth Readiness Fundraising and revenue scale potential, combined with offices in Switzerland, the U.S., and France, positions Medimaps for enterprise-grade deployments, international pilots, and channel partnerships with imaging vendors and hospital IT ecosystems.